TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Employment-based Reinforcement of Naltrexone Ingestion and Abstinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Volunteers were eligible to participate if they~* were between the ages of 18 and 65 years,~* were unemployed (i.e., reporting no work in the past 30 days and earning $200 in taxable income per month),~* self-reported injection drug use and had visible track marks (assessed via visual inspection),~* provided a urine sample that tested positive for both opiates and cocaine upon entry into detoxification,~* met DSM-IV-TR criteria for opiate dependence,~* were medically approved to be maintained on naltrexone by the study physician,~* and lived within reasonable commuting distance to the research unit (i.e., in Baltimore City and the immediate surrounding area).~Volunteers were excluded if they~* had active hallucinations, delusions, or a thought disorder;~* were judged to be of imminent threat to harm self or others;~* were currently incarcerated, in a halfway house, or under constant monitoring;~* were pregnant or breastfeeding;~* had serum aminotransferase levels over 3 times normal;~* required opiates for other medical problems (and thus could not be maintained on naltrexone, which would block the effects on any opiate);~* reported an interest in methadone treatment;~* had active tuberculosis;~* or had physical limitations that would prevent typing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Work Plus Naltrexone Prescription (Type: NO_INTERVENTION): Participants were prescribed naltrexone, but were not be required to ingest it to work. Participants could work and earn money, independent of whether or not they continued to take naltrexone.
- Work Plus Naltrexone Contingency (Type: EXPERIMENTAL): Participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose (employment-based reinforcement of naltrexone ingestion).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or more~* A diagnosis of ocular hypertension or open-angle glaucoma and prior use of timolol or prostaglandin.~* Meet specific IOP level at visit 1 (screening), visit 2 (run-in) and visit 3 (baseline).~* Meet specific visual acuity score~* Are willing to follow instructions~* Have provided a written informed consent~Exclusion Criteria:~* Females who are pregnant, nursing or planning pregnancy~* IOP of 35 mmHg or greater~* Diagnosis of angle-closure glaucoma or secondary glaucoma other than capsular or pigmentary glaucoma in either eye~* Suspected contraindication or hypersensitivity to study medications tafluprost or timolol (e.g. asthma, low pulse)or to wash-out medication brinzolamide~* Glaucoma filtration surgery or any other ocular surgery (including ocular laser procedures) within 6 months prior to Screening~* Use of contact lenses at Screening or during the study~* Presence of any abnormality or significant illness that could be expected to interfere with the patient safety or study parameters~* Current participation in another clinical trial within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Preservative-free timolol (Type: ACTIVE_COMPARATOR): None
- Preservative-free FDC and placebo (Type: EXPERIMENTAL): None
- Preservative-free tafluprost (Type: ACTIVE_COMPARATOR): None
- Preservative-free FDC (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with unilateral Ménière's disease (definite or probable, according to Committee on Hearing and Equilibrium guidelines, 1995) with hearing loss and presenting with recurrent vertigo, not responding to medical treatment for at least 6 months will be included. There should be normal, age appropriate hearing in the contralateral ear.~Exclusion Criteria:~* Patients with Ménière's disease in later stages (not having vertigo attacks).~* Age: patients older than 70 years at the start of the trial.~* Severe disability (e.g. neurological, orthopaedic, cardiovascular) or serious concurrent illness that might interfere with treatment or follow up.~* Active additional neuro-otological disorders that may mimic Ménière's disease (e.g. vestibular migraine, vertebro-basilar TIAs, acoustic neuroma) and thus will make the objective follow up difficult.~* Concurrent ear pathology that may interfere with transtympanic treatment (e.g. active middle ear disease).~* Family history of unexplained deafness (possibility of genetic susceptibility to gentamicin toxicity).~* History of known adverse/allergic reaction to steroids or gentamicin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Steroid (Methylprednisolone) (Type: EXPERIMENTAL): Steroid (Methylprednisolone)
- Gentamicin (Type: ACTIVE_COMPARATOR): Gentamicin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PHN with pain present for at least three months after the healing of a Herpes Zoster skin lesion.~* Subjects must have completed the Daily Pain Rating Scale in the electronic diary at least 4 times during screening and have an average daily pain rating score of greater than or equl to 4 during the 7 +/- 3 days prior to randomization (Visit 2).~Exclusion Criteria:~* History of neurolytic or neurosurgical therapy for PHN.~* Presence of any severe pain associated with conditions other than PHN that may confound the assessment or self-evaluation of the pain due to PHN.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Stage-Based Expert System for Teen Dating Violence Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Attending one of 20 participating schools~* In grade 9, 10, or 11~Exclusion Criteria:~* Parent submitted opt-out form

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Teen Choices (Type: EXPERIMENTAL): Teen Choices: A Program for Healthy Nonviolent Relationships
- Comparison (Type: OTHER): Health In Motion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female subjects between 18 and 55 years of age (inclusive)~Exclusion Criteria:~* Evidence or history of clinically significant disease;~* History of obstructive sleep apnea;~* Positive urine drug test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: EXPERIMENTAL): None
- Treatment B (Type: EXPERIMENTAL): None
- Treatment C (Type: EXPERIMENTAL): None
- Treatment D (Type: EXPERIMENTAL): None
- Treatment E (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Men and women at least 18 years old with evidence or a history of atherosclerosis involving the coronary, cerebral, or peripheral vascular systems by one or more of the following:~* history of myocardial infarction (heart attack)~* history of ischemic stroke (stroke due to a blocked artery)~* history of peripheral arterial disease~Exclusion Criteria:~* history of intracranial hemorrhage or of central nervous system (CNS) surgery, tumor, or aneurysm~* any bleeding disorder or abnormality~* sustained severe hypertension or valvular heart disease~* current or recent platelet count \<100,000 mm\^3~* planned or ongoing treatment with a blood thinning medication~* pregnancy~* any significant medical or physiological condition or abnormality that could put the subject at increased risk or limit the subject's ability to participate for the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
- Vorapaxar (Type: EXPERIMENTAL): one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* clinical evidence of stable, chronic (\>2 months) back pain related to intervertebral disc disease, nerve root entrapment, spondylolithesis, and osteoarthritis or other, similar nonmalignant conditions.~* unacceptable pain control despite currently taking a nonsteroidal anti-inflammatory drug considered at a therapeutic and/or tolerated dose or, subjects currently taking \</=2 short-acting opioid doses per day, or subjects taking 3-12 short-acting opioid doses per day.~Exclusion Criteria:~* receiving opioids at an average daily dose of \>90 mg of oral morphine equivalents or receiving more than 12 tablets per day of short-acting opioid-containing products.~* scheduled to have surgery (including dental) involving the use of preoperative or postoperative analgesics or anesthetics during the study period.~Other protocol-specific exclusion/inclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oxycodone (OXY)/acetaminophen (APAP) tablets and placebo transdermal patch (TDS) 5, 10, or 20
- OXY/APAP (Type: ACTIVE_COMPARATOR): 5 mg oxycodone/325 mg acetaminophen tablets
- BTDS (Type: EXPERIMENTAL): Buprenorphine transdermal patch 5, 10, or 20 mcg/hour

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: D-serine for Posttraumatic Stress Disorder Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Chronic PTSD (DSM-IV diagnosis)~Exclusion Criteria:~* Other psychiatric diagnosis~* Substance abuse~* Unstable medical condition

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Adjuvant 6 weeks treatment with placebo (\~2g /day)
- 2 (Type: EXPERIMENTAL): Adjuvant 6 weeks treatment with D-serine (\~2g /day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Monitoring of Postoperative Residual Neuromuscular Blockade in Laparoscopic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients aged over 18 years, planned to undergoing elective laparoscopic surgery under general anesthesia~Exclusion Criteria:~* Obesity BMI over 30 kg/m2~* Impairment of renal or/and liver function~* Allergy to rocuronium, sugammadex~* (Familial) history of malignant hyperthermia~* Taking medicines which is affecting neuromuscular function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neostigmine (Type: ACTIVE_COMPARATOR): At the end of surgery, administrating neostigmine to participants according to the protocol below:~when train-of-four (TOF) 2-3, administrating neostigmine 50mcg/kg when TOF 4 with fade, administrating neostigmine 40mcg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg
- Sugammadex (Type: ACTIVE_COMPARATOR): At the end of surgery, administrating sugammadex to participants according to the protocol below:~when TOF=0 and post-tetanic count (PTC)=1 or more, administrating sugammadex 4mg/kg when TOF=1 or more, administrating sugammadex 2mg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged 18 to 60 years, from both sex, and suffering from multiple sclerosis either primary progressive or secondary progressive without relapse within 2 years before inclusion.~2. Patients with EDSS score in the range of 2 to 6.5, inclusive~3. EDSS progression ≥ 1 point within 2 years before inclusion~Exclusion Criteria:~1. Disease other than MS responsible for clinical signs and/or MRI lesions~2. Secondary progressive MS with relapse in the 2 years before inclusion~3. Treatment with interferon or glatiramer acetate within four weeks prior to treatment allocation~4. Treatment with oral or systemic corticosteroids or ACTH within four weeks prior to treatment allocation.~5. Active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- masitinib 3 mg/kg/day (Type: EXPERIMENTAL): None
- masitinib 6 mg/kg/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects older than the minimum legal adult age (country specific);~* Acute symptomatic proximal DVT and/or symptomatic PE confirmed at the site by appropriate diagnostic imaging;~* Able to provide written informed consent~Exclusion Criteria:~* thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT and/or PE;~* More than 48 hours pre-treatment with anticoagulant therapy prior to randomization;~* Calculated Creatinine clearance (CrCL) \< 30 mL/min;~* significant liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis) or alanine transaminase (ALT) \>\\= 2 times the upper limit of normal (ULN), or total bilirubin (TBL) x 1.5 times the ULN;~* patients with active cancer for whom long term treatment with (LMW) heparin is anticipated;~* active bleeding or high risk for bleeding contraindicating treatment with (LMW) heparin or warfarin;~* chronic treatment with non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs);~* treatment with aspirin in a dosage of more than 100 mg/per day or dual antiplatelet therapy;~* concurrent treatment with potent P-gp inhibitors;~* subjects with any condition that, as judged by the investigator, would place the subject at increased risk of harm if he/she participated in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- heparin/edoxaban tosylate (Type: EXPERIMENTAL): None
- heparin/warfarin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Escalation Study of ONO-9054 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female subjects, aged 18-64 inclusive~* Body mass index (BMI) of 19-35 kg/m2 (inclusive)~* IOP measurement oculus uterque (OU, both eyes) \< 21 mm Hg (inclusive) at screening and Day -1~* Best corrected visual acuity (BCVA) 20/30 or better (Snellen Equivalent) at both the screening visit and Day -1~Exclusion Criteria:~* Any history of severe ocular trauma in either eye at any time~* Any history of previous intraocular or ocular laser surgery within the past 3 months or any refractive surgery procedure within the past 6 months of the screening visit in either eye~* Current or chronic history of ocular infection within the past 3 months of screening visit in either eye OR ongoing or recurrent ocular inflammation in either eye~* At the ophthalmic investigator's discretion, any subjects who have a history of any significant ocular conditions in either eye that would contraindicate the use of the study medication, or that might affect the study conduct, or the interpretation of the study results~* Use of any non-diagnostic topical ophthalmic solutions except for sponsor-recommended tear substitutes from admission to the study unit through the duration of the study~* History of clinically significant drug or food allergy, positive HIV, hepatitis B or C at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Eye drops 0.3 µg/mL (Type: EXPERIMENTAL): None
- Eye drops 1 µg/mL (Type: EXPERIMENTAL): None
- Eye drops 3 µg/mL (Type: EXPERIMENTAL): None
- Eye drops 10 µg/mL (Type: EXPERIMENTAL): None
- Eye drops 20 µg/mL (Type: EXPERIMENTAL): None
- Eye drops 30 µg/mL (Type: EXPERIMENTAL): None
- Eye drops placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective total hip replacement surgery or a revision of at least one component of a prosthesis implanted ≥ 6 months prior to study entry.~Exclusion Criteria:~* Any major orthopedic surgery in the 3 months prior to study start;~* Deep vein thrombosis or pulmonary embolism within the last 12 months or known post-phlebitic syndrome;~* High risk of bleeding;~* Known allergy to heparin or enoxaparin;~* Any contra-indications to the performance of venography;~* End stage renal disease or patient on dialysis.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semuloparin (Type: EXPERIMENTAL): Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment \[SRI\]) once daily for 7-10 days with an initial dose given 8 hours after surgery~Placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind
- Enoxaparin (Type: ACTIVE_COMPARATOR): Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment \[SRI\]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete